The paper discusses the features of antithrombotic therapy of
pregnant women suffering from congenital cardiopathologies.
Providing medical care to women suffering from cardiovascular
diseases and carrying a child is a difficult task due to the unique
maternal physiology, which causes profound changes in many
organ systems. First of all, such difficulties are caused by the
presence of the fetus, since individual approaches to the treatment of cardiac diseases of the mother can have an adverse
disease on the child. Conversely, the patient’s refusal of the necessary treatment due to potential harm to the fetus is fraught
with a bad outcome for both the mother and the child. Physiological adaptation of the mother’s body during pregnancy can
provoke cardiometabolic complications and cause thrombosis,
the consequences of which can be fatal. Accordingly, the development of approaches to the organization of antithrombotic
therapy of pregnant patients with cardiopathologies can contribute to improving the survival of the mother and fetus during
pregnancy, as well as create prerequisites for a successful delivery and postpartum recovery of the woman and child.